Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma. (3rd April 2018)

• Record Type: Journal Article
• Authors: Rodgers, Thomas D.; Reagan, Patrick M.
• Is Part Of: Expert opinion on emerging drugs. Volume 23:Number 2(2018)
• Page Start: 111
• Page End: 122
• Publication Date: 2018-04-03
• Subjects: Acalabrutinib -- Ibrutinib -- Idelalisib -- Copanlisib -- Phosphoinositide-3-kinase (PI3K) -- Bruton's Tyrosine Kinase (BTK) -- Non-Hodgkin's Lymphoma (NHL) -- B-Cell Receptor (BCR) -- Lymphoma; Drugs -- Research -- Handbooks, manuals, etc; Drugs -- Design -- Periodicals; 615.1072
• DOI: 10.1080/14728214.2018.1479396
• Languages: English
• ISSNs: 1472-8214

Abstract

ABSTRACT: Introduction : The B-cell receptor (BCR) pathway is a crucial aspect of mature lymphocytes and is maintained in B-cell neoplasms. Many small module inhibitors targeting kinases within the BCR pathway are approved, with others in development, offering alternative treatment options to standard chemoimmunotherapy. Areas covered : This review covers both approved inhibitors and investigational inhibitors of spleen tyrosine kinase (SYK), Bruton's tyrosine kinase (BTK), and phosphoinositide-3-kinase (PI3K) in the treatment of B-cell lymphomas. To collect relevant articles, a literature search was completed through the use of PubMed and abstracts from ASH and ASCO national meetings. Search terms including non-Hodgkin lymphoma, and BCR inhibitors, as well as the individual drug names, were utilized. The majority of included studies are dated from 2012 to March 2018. Expert opinion : BCR pathway inhibitors, such as ibrutinib and idelalisib, are novel treatments for non-Hodgkin lymphomas. While providing alternative treatment options to those with high-risk disease, poor functional status, and relapsed disease, outside of chronic lymphocytic leukemia (CLL), they have been limited to the relapsed/refractory setting. Their mechanisms of action, off/on-target effects, and resistance patterns create unique therapeutic dilemmas. It is our opinion that more specific inhibitors, as well as combination therapy, will define the future for BCR inhibitors.